• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Urogen Pharma Ltd (NQ: URGN )

    15.50 +0.01 (+0.06%)
    Streaming Delayed Price Updated: 10:49 AM EDT, Aug 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 49,936
    Open 15.51
    Bid (Size) 15.39 (2)
    Ask (Size) 15.50 (2)
    Prev. Close 15.49
    Today's Range 14.99 - 15.63
    52wk Range 10.60 - 23.70
    Shares Outstanding 36,130,121
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
    From UroGen Pharma Ltd.
    Via Business Wire
    URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024
    URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +1.91%
    +1.91%
    1 Month
    -9.99%
    -9.99%
    3 Month
    +17.34%
    +17.34%
    6 Month
    -17.55%
    -17.55%
    1 Year
    -27.81%
    -27.81%

    More News

    Read More
    UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
    Via Investor's Business Daily
    UroGen Pharma Stock Earns 91 RS Rating
    Via Investor's Business Daily
    NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
    From UroGen Pharma Ltd.
    Via Business Wire
    Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Pharma Appoints David Lin as New Chief Commercial Officer
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
    From UroGen Pharma Ltd.
    Via Business Wire
    URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Pharma to Participate at Upcoming Investor Conferences
    From UroGen Pharma Ltd.
    Via Business Wire
    New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
    From UroGen Pharma Ltd.
    Via Business Wire
    New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
    From UroGen Pharma Ltd.
    Via Business Wire
    UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
    From UroGen Pharma Ltd.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.